🚨 #ESMO26 Presidential Symposium II | HARMONi-GI1 Phase-3 trial

🥇 First trial to beat durva + GemCis in 1L BTC
Ivonescimab (PD-1/VEGF) + GemCis vs durva + GemCis, double-blind (N=682, China)

✅ mOS 14.9 vs 12.1 mo (HR 0.75)

✅ mPFS 8.4 vs 5.8 mo (HR 0.61)

✅ ORR 53.8% vs 32.5%

⚠️ G3–4 TEAEs 82% vs 72%

@OncoAlert @myESMO